Back to top
more

OncoCyte (OCX)

(Delayed Data from NSDQ)

$2.90 USD

2.90
21,566

-0.10 (-3.33%)

Updated Nov 4, 2024 03:52 PM ET

After-Market: $2.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock?

by Zacks Equity Research

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

OncoCyte (OCX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 0.00% and 23.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

by Debanjana Dey

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Will OncoCyte (OCX) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OncoCyte (OCX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of 10.00% and -52.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About OncoCyte (OCX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

OncoCyte (OCX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OncoCyte (OCX) delivered earnings and revenue surprises of -27.27% and 257.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Services Outlook Bright Amid Coronavirus Crisis

by Urmimala Biswas

Despite the coronavirus-led worldwide sales disruption, medical services is one of the few sectors witnessing industry-wide growth right now.

OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%

by Zacks Equity Research

OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Teladoc to Acquire MedecinDirect, Expand Overseas Business

by Zacks Equity Research

Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.

OncoCyte (OCX) in Focus: Stock Moves 13.1% Higher

by Zacks Equity Research

OncoCyte (OCX) was a big mover last session, as the company saw its shares rise more than 13% on the day.

    OncoCyte Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    OncoCyte Sees Hammer Chart Pattern: Time to Buy?

      Envision Healthcare to Go Private With Acquisition by KKR

      by Zacks Equity Research

      Envision Healthcare to become a private company on acquisition by private equity company KKR.

        Teladoc (TDOC) Buys Advance Medical to Boost Global Presence

        by Zacks Equity Research

        Teladoc's (TDOC) purchase of Advance Medical is in sync with its strategy to lap up complementary businesses and expedite growth.

          Can The Uptrend Continue for OncoCyte (OCX)?

          by Zacks Equity Research

          Investors certainly have to be happy with OncoCyte Corporation (OCX) and its short term performance